P319 Effects of elexacaftor/tezacaftor/ivacaftor (ETI) on nutrition parameters and resting energy expenditure (REE) in people with cystic fibrosis (pwCF)

Abstract

Cystic fibrosis (CF) is associated with increased energy requirement, energy loss and inadequate energy intake. With the approval of ETI, a highly effective CFTR-modulator therapy became available for 90% of pwCF. First studies have shown promising improvements in anthropometric parameters. We investigated the short-term change of the nutritional status under ETI and potential mechanisms of bodyweight (bw) gain.